drugset

Drugs / Siliankang

Follow last change Jul 2022 re-read 3 minutes ago

Siliankang

also known as Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live

Other / unclassified

Developed for: type 2 diabetes mellitus
Investigated by: Affiliated Hospital of Chengde Medical University · Chinese Academy of Sciences · First Affiliated Hospital of Harbin Medical University · Hangzhou Grand Biologic Pharmaceutical, Inc. · Peking Union Medical College Hospital · The Affiliated Hospital of Inner Mongolia Medical University
+1 more
· The First Affiliated Hospital of Zhengzhou University

Trials 1

today NCT04982380 · Ph 4

20222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT04982380	Jul 2021 → Jul 2022	type 2 diabetes mellitus	Peking Union Medical College Hospital	Unknown	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Siliankang	“Efficacy and Safety of Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) in Patients With Type 2 Diabetes and Constipation: a...” NCT04982380 ↗
Known as	Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live	“Efficacy and Safety of Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) in Patients With Type 2 Diabetes and Constipation: a...” NCT04982380 ↗
Modality	Other / unclassified	“microecological preparation” NCT04982380 ↗
Route	Oral	“3 tablets p.o. tid for 12 weeks” NCT04982380 ↗